Nishant K Singh
Overview
Explore the profile of Nishant K Singh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
489
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tano-Menka R, Singh N, Muzhingi I, Li X, Mandanas M, Kaseke C, et al.
Structure
. 2024 May;
32(8):1121-1136.e5.
PMID: 38733995
Immunogenetic studies have shown that specific HLA-B residues (67, 70, 97, and 156) mediate the impact of HLA class I on HIV infection, but the molecular basis is not well...
2.
Singh N, Singh N, Verma R, Diwan A
Bioengineering (Basel)
. 2024 Apr;
11(4).
PMID: 38671766
(1) Background: Intervertebral disc degeneration has been linked to obesity; its potential mechanical effects on the intervertebral disc remain unknown. This study aimed to develop and validate a patient-specific model...
3.
Huisman B, Guan N, Ruckert T, Garner L, Singh N, McMichael A, et al.
Nat Commun
. 2023 Aug;
14(1):5264.
PMID: 37644057
No abstract available.
4.
Huisman B, Guan N, Ruckert T, Garner L, Singh N, McMichael A, et al.
Nat Commun
. 2023 Aug;
14(1):4809.
PMID: 37558657
HLA-E is a non-classical class I MHC protein involved in innate and adaptive immune recognition. While recent studies have shown HLA-E can present diverse peptides to NK cells and T...
5.
Nguyen K, Roerden M, Copeland C, Backlund C, Klop-Packel N, Remba T, et al.
Elife
. 2023 Aug;
12.
PMID: 37548358
Cancer immunotherapies, in particular checkpoint blockade immunotherapy (CBT), can induce control of cancer growth, with a fraction of patients experiencing durable responses. However, the majority of patients currently do not...
6.
Singh N, Alonso J, Devlin J, Keller G, Gray G, Chiranjivi A, et al.
Nat Commun
. 2022 Nov;
13(1):7189.
PMID: 36424374
MHC restriction, which describes the binding of TCRs from CD4 T cells to class II MHC proteins and TCRs from CD8 T cells to class I MHC proteins, is a...
7.
Grace B, Backlund C, Morgan D, Kang B, Singh N, Huisman B, et al.
Front Immunol
. 2022 Jul;
13:886683.
PMID: 35812387
While immune checkpoint blockade results in durable responses for some patients, many others have not experienced such benefits. These treatments rely upon reinvigorating specific T cell-antigen interactions. However, it is...
8.
Nathan A, Rossin E, Kaseke C, Park R, Khatri A, Koundakjian D, et al.
Cell
. 2021 Jul;
184(17):4401-4413.e10.
PMID: 34265281
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that escape convalescent and vaccine-induced antibody responses has renewed focus on the development of broadly protective T-cell-based vaccines. Here,...
9.
Kaseke C, Park R, Singh N, Koundakjian D, Bashirova A, Garcia Beltran W, et al.
Cell Rep
. 2021 Jul;
36(2):109378.
PMID: 34260940
Defining factors that govern CD8 T cell immunodominance is critical for the rational design of vaccines for viral pathogens. Here, we assess the contribution of human leukocyte antigen (HLA) class-I-peptide...
10.
Agrawal S, Singh N, Upadhyay R, Singh G, Singh Y, Singh S, et al.
Materials (Basel)
. 2021 Jun;
14(11).
PMID: 34072710
In recent years, the engineering implications of carbon nanotubes (CNTs) have progressed enormously due to their versatile characteristics. In particular, the role of CNTs in improving the tribological performances of...